HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $38 Price Target
Benzinga · 09/15 10:11
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $38 price target.